Revelation Biosciences Deploys Poison Pill to Fend Off Hostile Bids
REVB is trading near its 52-week low of $0.875 (13% above the low) on light trading volume (0.3× avg).
Summary
Revelation Biosciences has adopted a poison pill with a 10% trigger to deter hostile takeovers. The plan is standard for companies facing financial distress and potential undervaluation, giving the board time to negotiate a fair deal if an acquirer emerges.
Key Events · Corporate Governance and Compliance · REVB
-
Poison Pill Adopted
The board adopted a stockholder rights plan with a 10% trigger—15% for passive investors. If activated, all other stockholders gain the right to buy shares at a 50% discount, severely diluting the acquirer.
-
Rights Dividend Declared
One Right will be distributed per common share to holders of record on July 21, 2026. The Rights are not immediately exercisable and trade with the common stock until a triggering event occurs.
-
Expiration and Ratification
The Rights expire on July 10, 2027, unless stockholders ratify the plan, which would extend the term to July 10, 2029. Before a trigger, the board can redeem the Rights at $0.001 each.
-
Defensive Context
The adoption follows a going concern warning, recent reverse split authorization, and a low market cap, suggesting the board is protecting against opportunistic takeovers while seeking financing or strategic alternatives.
Analysis · REVB · Life Sciences
To shield against unsolicited takeovers, Revelation Biosciences has put in place a stockholder rights plan—commonly called a poison pill—with a 10% trigger. The move erects a formidable barrier to hostile acquirers by threatening massive dilution for anyone who crosses the ownership threshold without board consent. For a micro‑cap company already carrying a going concern warning and fresh authorization for a reverse split, the adoption signals that the board is actively guarding against opportunistic accumulations while it works to extend the cash runway. The plan sunsets in one year unless stockholders ratify it, which would push the expiration out to three years.
At the time of this filing, REVB was trading at $0.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.9M. The 52-week trading range was $0.88 to $12.88. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.